T. Rowe Price Associates’s Larimar Therapeutics LRMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $62K | Buy |
21,301
+4,991
| +31% | +$14.5K | ﹤0.01% | 2973 |
|
|
2025
Q1 | $36K | Buy |
16,310
+858
| +6% | +$1.89K | ﹤0.01% | 2963 |
|
|
2024
Q4 | $60K | Buy |
15,452
+1,992
| +15% | +$7.74K | ﹤0.01% | 2898 |
|
|
2024
Q3 | $89K | Hold |
13,460
| – | – | ﹤0.01% | 2841 |
|
|
2024
Q2 | $98K | Buy |
+13,460
| New | +$98K | ﹤0.01% | 2762 |
|
|
2019
Q3 | – | Sell |
-3,901
| Closed | -$56K | – | 2528 |
|
|
2019
Q2 | $56K | Sell |
3,901
-42
| -1% | -$603 | ﹤0.01% | 2502 |
|
|
2019
Q1 | $130K | Sell |
3,943
-68,617
| -95% | -$2.26M | ﹤0.01% | 2443 |
|
|
2018
Q4 | $4.31M | Sell |
72,560
-31,147
| -30% | -$1.85M | ﹤0.01% | 1419 |
|
|
2018
Q3 | $14.5M | Buy |
+103,707
| New | +$14.5M | ﹤0.01% | 1308 |
|
|
2017
Q1 | – | Sell |
-5,910
| Closed | -$226K | – | 2583 |
|
|
2016
Q4 | $226K | Sell |
5,910
-11
| -0.2% | -$421 | ﹤0.01% | 2346 |
|
|
2016
Q3 | $235K | Hold |
5,921
| – | – | ﹤0.01% | 2304 |
|
|
2016
Q2 | $426K | Sell |
5,921
-946
| -14% | -$68.1K | ﹤0.01% | 2023 |
|
|
2016
Q1 | $550K | Sell |
6,867
-1,997
| -23% | -$160K | ﹤0.01% | 1929 |
|
|
2015
Q4 | $669K | Sell |
8,864
-28,418
| -76% | -$2.14M | ﹤0.01% | 1834 |
|
|
2015
Q3 | $14.3M | Sell |
37,282
-5,351
| -13% | -$2.05M | ﹤0.01% | 1206 |
|
|
2015
Q2 | $17.7M | Sell |
42,633
-1,747
| -4% | -$726K | ﹤0.01% | 1173 |
|
|
2015
Q1 | $21.1M | Buy |
+44,380
| New | +$21.1M | ﹤0.01% | 1110 |
|